{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T05:35:39Z","timestamp":1766208939100,"version":"3.48.0"},"reference-count":20,"publisher":"Japanese Society of Internal Medicine","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,12,15]]},"DOI":"10.2169\/internalmedicine.5363-25","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T18:07:32Z","timestamp":1750270052000},"page":"3493-3501","source":"Crossref","is-referenced-by-count":0,"title":["Long-term Efficacy and Safety of Amifampridine Phosphate (Firdapse&lt;sup&gt;\u00ae&lt;\/sup&gt;) in Japanese Patients with Lambert-Eaton Myasthenic Syndrome (LMS-005 Study)"],"prefix":"10.2169","volume":"64","author":[{"given":"Yuki","family":"Hatanaka","sequence":"first","affiliation":[{"name":"Department of Neurology, Teikyo University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madoka","family":"Mori-Yoshimura","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimiaki","family":"Utsugisawa","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hanamaki General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Tsujino","sequence":"additional","affiliation":[{"name":"Department of Neurology and Strokology, Nagasaki University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuya","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nagaoka Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Yabe","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hokkaido University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Igarashi","sequence":"additional","affiliation":[{"name":"DyDo Pharma, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakatsu","family":"Motomura","sequence":"additional","affiliation":[{"name":"Medical Engineering Course, Nagasaki Institute of Applied Science, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Motomura M, Lang B, Johnston I, Palace J, Vincent A, Newsom-Davis J. Incidence of serum anti-P\/Q-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurol Sci 147: 35-42, 1997.","DOI":"10.1016\/S0022-510X(96)05303-8"},{"key":"2","unstructured":"2. Lambert E, Eaton L, Rooke E. Defect of neuromuscular conduction associated with malignant neoplasms. Am J Physiol 187: 612-613, 1956."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Augustine GJ. Regulation of transmitter release at the squid giant synapse by presynaptic delayed rectifier potassium current. J Physiol 431: 343-364, 1990.","DOI":"10.1113\/jphysiol.1990.sp018333"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Verschuuren JJGM, Wirtz PW, Titulaer MJ, Willems LNA, van Gerven J. Available treatment options for the management of Lambert-Eaton myasthenic syndrome. Expert Opin Pharmacother 7: 1323-1336, 2006.","DOI":"10.1517\/14656566.7.10.1323"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Yoshikawa H, Adachi Y, Nakamura Y, et al. Nationwide survey of Lambert-Eaton myasthenic syndrome in Japan. BMJ Neurol Open 4: e000291, 2022.","DOI":"10.1136\/bmjno-2022-000291"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Murai H, Utsugisawa K, Motomura M, Imai T, Uzawa A, Suzuki S. The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert-Eaton myasthenic syndrome. Clin Exp Neuroimmunol 14: 19-27, 2023.","DOI":"10.1111\/cen3.12739"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Oh SJ, Shcherbakova N, Kostera-Pruszczyk A, et al.; LEMS Study Group. Amifampridine phosphate (Firdapse<sup>\u00ae<\/sup>) is effective and safe in a phase 3 clinical trial in LEMS. Muscle Nerve 53: 717-725, 2016.","DOI":"10.1002\/mus.25070"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Shieh P, Sharma K, Kohrman B, Oh SJ. Amifampridine phosphate (Firdapse) is effective in a confirmatory phase 3 clinical trial in LEMS. J Clin Neuromuscul Dis 20: 111-119, 2019.","DOI":"10.1097\/CND.0000000000000239"},{"key":"9","unstructured":"9. FIRDAPSE<sup>\u00ae<\/sup> (amifampridine) tablets, for oral use. Highlight of prescribing information [Internet]. [updated 2024 May; cited 2025 Mar 18]. Available from: https:\/\/firdapse.com\/pdfs\/firdapse-pi.pdf"},{"key":"#cr-split#-10.1","unstructured":"10. FIRDAPSE 10 mg tablets. Summary of product characteristics [Internet]. [updated 2022 Apr 28"},{"key":"#cr-split#-10.2","unstructured":"cited 2025 Mar 18]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/11539\/smpc\/print"},{"key":"11","unstructured":"11. Japanese Committee of Clinical Guidelines for Myasthenia Gravis. Japanese clinical guidelines 2014 for myasthenia gravis. Nankodo, Tokyo, 2014 (in Japanese)."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Katzberg HD, Barnett C, Merkies ISJ, Bril V. Minimal clinically important difference in myasthenia gravis: outcomes from a randomized trial. Muscle Nerve 49: 661-665, 2014.","DOI":"10.1002\/mus.23988"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Nakao YK, Motomura M, Fukudome T, et al. Seronegative Lambert-Eaton myasthenic syndrome: study of 110 Japanese patients. Neurology 59: 1773-1775, 2002.","DOI":"10.1212\/01.WNL.0000037485.56217.5F"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. O&apos;Neill JH, Murray NMF, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome: a review of 50 cases. Brain 111: 577-596, 1988.","DOI":"10.1093\/brain\/111.3.577"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Titulaer MJ, Wirtz PW, Willems LNA, van Kralingen KW, Smitt PAES, Verschuuren JJGM. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol 26: 4276-4281, 2008.","DOI":"10.1200\/JCO.2008.17.5133"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. McEvoy KM, Windebank AJ, Daube JR, Low PA. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med 321: 1567-1571, 1989.","DOI":"10.1056\/NEJM198912073212303"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Sanders DB. 3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS). Ann NY Acad Sci 841: 811-816, 1998.","DOI":"10.1111\/j.1749-6632.1998.tb11022.x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Lundh H, Nilsson O, Ros\u00e9n I, Johansson S. Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome. Acta Neurol Scand 88: 136-140, 1993.","DOI":"10.1111\/j.1600-0404.1993.tb04205.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Haroldsen PE, Garovoy MR, Musson DG, et al. Genetic variation in aryl <i>N<\/i>-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate. Pharmacol Res Perspect 3: e00099, 2015.","DOI":"10.1002\/prp2.99"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/24\/64_5363-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T03:39:53Z","timestamp":1766201993000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/24\/64_5363-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":20,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5363-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"type":"print","value":"0918-2918"},{"type":"electronic","value":"1349-7235"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"article-number":"5363-25"}}